EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Evolus, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$7.36+0.26 (+3.66%)
Close on Oct 19, 2026
- Market cap
- $485.24M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Gross margin
66.3%−1.3 pts over 5 years
Operating margin
-11.0%+259.7 pts over 5 years
Net margin
-17.4%+270.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +11.6% | +26.0% | +39.4% | – | |
| Gross profit | +8.1% | +30.0% | +38.8% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -5016.6% | 587.4% | |
| Return on assets | – | -72.5% | -22.5% | |
| Current ratio | – | 0.71 | 1.90 | |
| Debt to equity | – | – | -6.32 | |
| Net debt to EBITDA | – | – | -3.67× | |
| Interest coverage | – | – | -1.7× | |
| Inventory turnover | – | 3.7× | 5.1× | |
| Capex to revenue | – | 1.4% | 1.2% | |
| Diluted shares | – | 34M | 64M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Evolus generated $212.57M from operations and spent $7.40M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$212.57M
Used
$7.40M
Capital expenditure$7.40M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-17.4%
×Asset turnover1.30×
×Equity multiplier-26.07×
=Return on equity, FY2025587.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -17.4% | 1.30× | -26.07× | 587.4% |
| FY2024 | -18.9% | 1.26× | -27.80× | 664.9% |
| FY2023 | -30.5% | 1.10× | -167.57× | 5633.3% |
| FY2022 | -50.1% | 0.68× | 4.34× | -148.3% |
| FY2021 | -47.0% | 0.43× | 52.32× | -1049.8% |
| FY2020 | -288.3% | 0.25× | 69.17× | -5016.6% |
| FY2019 | -257.8% | 0.17× | 2.52× | -109.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$51.64M
- Cash generatingOperating cash flow above zero-$42.27M
- Return on assets improvedROA up on the prior year-26.7% → -22.2%
- Earnings backed by cashOperating cash flow above net income-$42.27M vs -$51.64M
- Less leverageLong-term debt to assets fell52.2% → 64.7%
- Better liquidityCurrent ratio rose2.40 → 1.90
- No dilutionShare count did not rise62M → 64M
- Gross margin improvedGross margin up on the prior year68.46% → 66.33%
- More efficientAsset turnover rose1.41 → 1.28